Nektar Therapeutics (NKTR) awards 16,500 stock options to Chief R&D Officer
Rhea-AI Filing Summary
Nektar Therapeutics reported that Chief R&D Officer Jonathan Zalevsky received a grant of stock options covering 16,500 shares of common stock at an exercise price of $15.1500 per share, expiring on 2032-12-12. These options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan with both performance-based and time-based vesting. The Organization and Compensation Committee determined on July 23, 2026 that the performance condition was satisfied, and the options vested on July 24, 2026, subject to continued monthly pro-rata time-based vesting over five years from the grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Zalevsky Jonathan
Role
Chief R&D Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option F1, F2 | 16,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option — 16,500 shares (Direct)
Footnotes (2)
- F1. These stock options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of five years from the date of grant.
- F2. The Organization and Compensation Committee of the Board of Directors of the Issuer determined on July 23, 2026 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on July 24, 2026 (subject to remaining time-based vesting requirements).
Key Figures
Stock options granted: 16500.0000 shares
Exercise price: $15.1500 per share
Underlying common shares: 16500.0000 shares
+5 more
8 metrics
Stock options granted
16500.0000 shares
Grant to Chief R&D Officer Jonathan Zalevsky
Exercise price
$15.1500 per share
Conversion or exercise price of the stock options
Underlying common shares
16500.0000 shares
Common stock underlying the reported stock options
Expiration date
2032-12-12
Expiration of the reported stock options
Grant date
December 13, 2024
Original grant date under the 2017 Amended and Restated Performance Incentive Plan
Performance condition determination
July 23, 2026
Date Committee determined performance-based vesting requirement was satisfied
Vesting commencement linked date
July 24, 2026
Date on which the options vested subject to remaining time-based vesting
Time-based vesting period
5 years
Monthly pro-rata vesting over five years from December 13, 2024
Key Terms
performance-based vesting, time-based vesting, 2017 Amended and Restated Performance Incentive Plan, Organization and Compensation Committee
4 terms
performance-based vesting financial
"were subject to both performance-based and time-based vesting requirements"
time-based vesting financial
"The time-based vesting is on a monthly pro-rata basis over a period of five years"
Time-based vesting is a schedule that gives employees or contractors ownership of granted stock or options gradually as they remain with a company, like unlocking rewards in a loyalty program the longer you stick around. For investors, it matters because it affects future share supply, management incentives and staff retention — all of which can influence company performance and dilution of existing shareholders.
2017 Amended and Restated Performance Incentive Plan financial
"These stock options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan"
Organization and Compensation Committee financial
"The Organization and Compensation Committee of the Board of Directors of the Issuer determined"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Nektar Therapeutics (NKTR) report for Jonathan Zalevsky?
Nektar Therapeutics reported a grant of stock options to Chief R&D Officer Jonathan Zalevsky covering 16,500 shares of common stock. The options were granted under the 2017 Amended and Restated Performance Incentive Plan with performance-based and time-based vesting conditions.
How many stock options were granted to the NKTR Chief R&D Officer and at what exercise price?
Jonathan Zalevsky received 16,500.0000 stock options with an exercise price of $15.1500 per share. These options relate to an equivalent number of shares of Nektar Therapeutics common stock as the underlying security upon exercise, if vesting conditions are met.
What are the vesting terms of the Nektar Therapeutics (NKTR) stock options granted on December 13, 2024?
The options granted on December 13, 2024 vest based on both performance-based and time-based requirements. Time-based vesting occurs on a monthly pro-rata basis over five years from the grant date, subject to the satisfied performance condition.
When was the performance-based vesting condition satisfied for the NKTR stock options?
The Organization and Compensation Committee determined on July 23, 2026 that the performance-based vesting requirement was satisfied. As a result, the stock options vested on July 24, 2026, while remaining subject to ongoing time-based vesting requirements over the five-year schedule.
What is the expiration date of the Nektar Therapeutics (NKTR) stock options granted to Jonathan Zalevsky?
The reported stock options held by Jonathan Zalevsky expire on 2032-12-12. After this expiration date, any unexercised portion of the 16,500.0000 options at the $15.1500 exercise price will no longer be exercisable under the plan’s terms.
Were the NKTR stock option transactions reported under a Rule 10b5-1 trading plan?
The report indicates the Rule 10b5-1 trading plan affirmation box was not checked. This means the company did not identify this stock option grant and vesting event as occurring pursuant to an affirmatively disclosed Rule 10b5-1 trading plan.